SyedZafarIqbalMD

Neuropsychiatry

Assistant Professor Baylor College of Medicine

Dr. Iqbal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

The Charles Shagass, MD Award for scholarly Achievement During Residency Training Temple university Hospital, 2016
The John R. Benson, M.D Award for outstanding Teaching skills during Residency training Temple University hospital, 2015

PubMed

Recent Advances in Psychopharmacology: From Bench to Bedside Novel Trends in Schizophrenia.
Asim A Shah, Syed Z Iqbal
Journal of Personalized Medicine. 2023-02-25
12 citations
Ketamine for depression clinical issues.
Syed Z Iqbal, Sanjay J. Mathew
Advances in Pharmacology. 2020-01-01
15 citations
Longer-term open-label study of adjunctive riluzole in treatment-resistant depression.
Hitoshi Sakurai, Christina Dording, Albert Yeung, Simmie L. Foster, Felipe A. Jain
Journal of Affective Disorders. 2019-11-01

Journal Articles

Borderline Personality Disorder: Impact, Overlap, and Comorbidities
Syed Z. Iqbal, MD; Lindsay Nicole French-Rosas, MD; Sophia Banu, MD; Jin Yong Han, MD; and Asim A. Shah, MD, Psychiatric Annals
Telepsychiatry: Benefits, Limitations, and Ethical Issues
IqbalSZ, MD; Czelusta KL, MD; HashimA, MD; WILLIE J. MORGAN, MBA, MAHS; ASIM A. SHAH, MD, Directions in Psychiatry, 4/2020
Vaping and its effects on physical health
Syed Z. Iqbal, MD; Benjamin T. Li, MD; Lubna Khawaja MD; Asim A. Shah, MD, Directions in Psychiatry, 3/6/2020
 Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.
Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, Soleimani L, Charney DS, Foulkes AL, Mathew SJ, Depress Anxiety., 3/24/2014
 Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.
Haile CN, Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Foulkes A, Iqbal S, Mahoney JJ , De La Garza R , Charney DS, Newton TF, Mathew SJ, J Neuropsychopharmacol. 2014 Feb;17(2):331-6., 2/17/2014
 Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial
Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ. Am J, American Journal of Psychiatry, 10/17/2013
Join now to see all